EE9800161A - Vähivaktsiin ja selle valmistamismeetod - Google Patents

Vähivaktsiin ja selle valmistamismeetod

Info

Publication number
EE9800161A
EE9800161A EE9800161A EE9800161A EE9800161A EE 9800161 A EE9800161 A EE 9800161A EE 9800161 A EE9800161 A EE 9800161A EE 9800161 A EE9800161 A EE 9800161A EE 9800161 A EE9800161 A EE 9800161A
Authority
EE
Estonia
Prior art keywords
preparation
cancer vaccine
vaccine
cancer
Prior art date
Application number
EE9800161A
Other languages
English (en)
Other versions
EE03778B1 (et
Inventor
Schmidt Walter
L. Birnstiel Max
Schweighoffer Tam�s
Steinlein Peter
Buschle Michael
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19543649A external-priority patent/DE19543649C2/de
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of EE9800161A publication Critical patent/EE9800161A/et
Publication of EE03778B1 publication Critical patent/EE03778B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EE9800161A 1995-11-23 1996-11-21 Vähivaktsiin ja selle valmistamismeetod EE03778B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19543649A DE19543649C2 (de) 1995-11-23 1995-11-23 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
PCT/EP1996/005126 WO1997019169A1 (de) 1995-11-23 1996-11-21 Tumorvakzine und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
EE9800161A true EE9800161A (et) 1998-12-15
EE03778B1 EE03778B1 (et) 2002-06-17

Family

ID=26020603

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800161A EE03778B1 (et) 1995-11-23 1996-11-21 Vähivaktsiin ja selle valmistamismeetod

Country Status (24)

Country Link
US (1) US20020085997A1 (et)
EP (1) EP0866851A1 (et)
JP (1) JP2000502052A (et)
KR (1) KR19990067653A (et)
CN (1) CN1202931A (et)
AR (1) AR004341A1 (et)
AU (1) AU720131B2 (et)
BG (1) BG62999B1 (et)
BR (1) BR9611466A (et)
CA (1) CA2238176A1 (et)
CO (1) CO4520254A1 (et)
CZ (1) CZ158998A3 (et)
EE (1) EE03778B1 (et)
HU (1) HUP0000318A3 (et)
NO (1) NO982329D0 (et)
NZ (1) NZ322910A (et)
PL (1) PL188537B1 (et)
RO (1) RO115275B1 (et)
RU (1) RU2206329C2 (et)
SK (1) SK66998A3 (et)
TR (1) TR199800912T2 (et)
TW (1) TW514530B (et)
UY (2) UY24367A1 (et)
WO (1) WO1997019169A1 (et)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50101B (sr) † 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
CA2278678A1 (en) * 1997-01-31 1998-08-06 Research Corporation Technologies, Inc. Cancer immunotherapy with semi-allogeneic cells
DE69731950T2 (de) * 1997-08-22 2005-05-19 Science Park Raf S.P.A. Tumorvakzinierung mittels Verwendung autologer oder HLA-verwandter Antigen präsentierender Zellen (APC), die mit einem Tumorantigen sowie einem eine Immunantwort hervorrufenden Fremdantigen transduziert sind
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
JP2002506886A (ja) * 1998-03-20 2002-03-05 ジェンザイム・コーポレーション 抗腫瘍免疫亢進
FR2807661A1 (fr) * 2000-04-14 2001-10-19 Univ Nantes Agent et procede pour la simulation de lymphocytes t specifiques et lymphocytes t obtenus
WO2003025569A1 (en) * 2001-09-18 2003-03-27 Kyogo Itoh Method of detecting cellular immunity and application thereof to drugs
RU2203683C1 (ru) * 2001-09-20 2003-05-10 НИИ онкологии им. проф. Н.Н. Петрова Способ иммунотерапии костно-мозговыми дендритными клетками больных солидными опухолями
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
RU2385163C2 (ru) * 2003-08-25 2010-03-27 ОнкоМун Профилактическая противораковая вакцина
RU2267326C2 (ru) * 2004-03-16 2006-01-10 ГУН НИИ онкологии им. проф. Н.Н. Петрова Минздрава РФ Способ иммунотерапии опухолевым лизатом с адъювантом беталейкин больных солидными опухолями
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
EP1850874B1 (en) * 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
WO2006105255A2 (en) 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
SI1806358T1 (sl) * 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
WO2014012051A1 (en) * 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
JP6710004B2 (ja) 2016-03-15 2020-06-17 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
US20240156869A1 (en) * 2021-03-12 2024-05-16 T-Cure Bioscience, Inc. Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
EP0569678A3 (de) * 1992-03-13 1994-10-26 Yeda Res & Dev Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen.

Also Published As

Publication number Publication date
KR19990067653A (ko) 1999-08-25
TW514530B (en) 2002-12-21
CN1202931A (zh) 1998-12-23
RO115275B1 (ro) 1999-12-30
HUP0000318A2 (hu) 2000-06-28
PL188537B1 (pl) 2005-02-28
PL326756A1 (en) 1998-10-26
BG62999B1 (bg) 2001-01-31
BG102439A (en) 1999-01-29
TR199800912T2 (xx) 1998-08-21
UY24430A1 (es) 1997-07-01
SK66998A3 (en) 1998-12-02
NZ322910A (en) 2000-05-26
HUP0000318A3 (en) 2002-02-28
BR9611466A (pt) 1999-05-18
CA2238176A1 (en) 1997-05-29
UY24367A1 (es) 2000-10-31
CZ158998A3 (cs) 1999-06-16
AU720131B2 (en) 2000-05-25
US20020085997A1 (en) 2002-07-04
WO1997019169A1 (de) 1997-05-29
EP0866851A1 (de) 1998-09-30
JP2000502052A (ja) 2000-02-22
AU7694796A (en) 1997-06-11
CO4520254A1 (es) 1997-10-15
EE03778B1 (et) 2002-06-17
AR004341A1 (es) 1998-11-04
NO982329D0 (no) 1998-05-22
RU2206329C2 (ru) 2003-06-20

Similar Documents

Publication Publication Date Title
EE9800161A (et) Vähivaktsiin ja selle valmistamismeetod
EE03976B1 (et) Erütromütsiinid ja nende valmistamise meetod
FI973402L (fi) Uusia proteiineja ja menetelmiä proteiinien tuottamiseksi
EE9800053A (et) Kõrge efektiivsusega segusti ja selle valmistamise meetod
FI973426L (fi) Bentsopyraania sisältävät yhdisteet ja menetelmä niiden valmistamiseksi
FI973750L (fi) 2-metyylitienobentsodiatsepiinin valmistus ja kiteiset muodot
FI20060617L (fi) Arakidonihappo ja menetelmä sen valmistamiseksi ja sen käyttö
FI964028L (fi) Uusi farmaseuttinen formulaatio ja menetelmä
HUT77366A (hu) Daganatellenes kakaóextraktumok, ezek előállítási eljárása, valamint alkalmazása
FI973733L (fi) Farmaseuttinen valmiste ja menetelmä sen valmistamiseksi
FI950886L (fi) Kreatiinijuoma ja sen valmistusmenetelmä
FI973195L (fi) Hairuston uutteet, menetelmä niiden valmistamiseksi ja niiden käyttö
EE9800234A (et) Ravimeetod ja farmatseutiline kompositsioon
FI972245A7 (fi) Meso-monojodisubstituoidut tetramakrosykliset yhdisteet sekä niiden valmistus- ja käyttömenetelmät
KR970000228A (ko) S-에토돌락의 경구용 제제
FI973797L (fi) Steriili tiputettava oftalmologinen geelivalmiste ja menetelmä sen valmistamiseksi
FI980246A0 (fi) Menetelmä keittimen käyttämiseksi ja keitin
FI951060A7 (fi) Formulaatioita ja hoitomenetelmiä
NO973826D0 (no) Ny anvendelse av preparater inneholdende perlemor
FI952297A7 (fi) Fluoridia vapauttava hammaspohjustekoostumus ja menetelmä sen käyttämiseksi
FI963325A7 (fi) Inhibiinikoostumukset ja menetelmät niiden käyttämiseksi
EE9800075A (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
EE03687B1 (et) Furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
FI973434A7 (fi) Aminotetralonijohdannaisia ja menetelmä niiden valmistamiseksi
BR9708979A (pt) Complexo imunogénico utilização do mesmo vacina processo para a preparação de um complexo imunogenico e utilização de uma proteína

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

MM4A Lapsed by not paying the annual fees

Effective date: 20041121